Laninamivir
Laninamivir
 |
| Systematic (IUPAC) name |
|---|
|
(4S,5R,6R)-5-acetamido-4-carbamimidamido-6-[(1R,2R)-3-hydroxy-2-methoxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid |
| Clinical data |
|---|
Routes of
administration |
Inhalation |
|---|
| Identifiers |
|---|
| CAS Number |
203120-17-6  N |
|---|
| ATC code |
none |
|---|
| PubChem |
CID 502272 |
|---|
| ChemSpider |
439182  Y |
|---|
| UNII |
B408IW3GL5 Y |
|---|
| ChEMBL |
CHEMBL466246 Y |
|---|
| Chemical data |
|---|
| Formula |
C13H22N4O7 |
|---|
| Molar mass |
346.33638 g/mol |
|---|
O=C(O)C=1O[C@@H]([C@H](OC)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](/N=C(\N)N)C=1
|
InChI=1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1 YKey:QNRRHYPPQFELSF-CNYIRLTGSA-N Y
|
| NY (what is this?) (verify) |
|---|
Laninamivir (CS-8958) is a neuraminidase inhibitor which is being researched for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B.[1] It is currently in Phase III clinical trials.[2] It is a long-acting neuraminidase inhibitor administered by nasal inhalation.[3]
Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals [4] and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US.[5] It is under clinical evaluations in other countries.[3]
References
- ↑ Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S (January 2009). "CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity". Antimicrobial Agents and Chemotherapy 53 (1): 186–92. doi:10.1128/AAC.00333-08. PMC 2612152. PMID 18955520.
- ↑ Hayden F (January 2009). "Developing new antiviral agents for influenza treatment: what does the future hold?". Clinical Infectious Diseases. 48. Suppl 1 (S1): S3–13. doi:10.1086/591851. PMID 19067613.
- 1 2 Samson, M; Pizzorno, A; Abed, Y; Boivin, G (May 2013). "Influenza virus resistance to neuraminidase inhibitors.". Antiviral Research 98 (2): 174–85. doi:10.1016/j.antiviral.2013.03.014. PMID 23523943.
- ↑ http://www.biotapharma.com
- ↑ http://www.biotapharma.com/?page=1021001&subpage=1021019